By destabilizing the cancer cells, the ketogenic diet created a microenvironment in which the triple-drug therapy designed by TGen a combination of gemcitabine, nab-paclitaxel and cisplatin was more effective at knocking out the tumor, according to the study.
“By limiting glucose availability, the ketogenic diet may promote chemotherapy efficacy,” said TGen Distinguished Professor Daniel D. Von Hoff, M.D., considered one of the nation’s foremost authorities on pancreatic cancer. Dr. Von Hoff is one of the study authors and designers of the therapy.
In addition, the ketogenic diet was shown to have a favorable impact on antitumor immunity by inducing pro-inflammatory tumor gene expression, which further weakened the cancer.
Clinical trials at five locations
To test these laboratory findings, researchers initiated a clinical trial of up to 40 patients at five centers nationwide: HonorHealth in Scottsdale, USC in Los Angeles, Nuvance Health in Connecticut, Atlantic Health System in New Jersey, and South Texas Accelerated Research Therapeutics in San Antonio.
The clinical trial will test whether adding a ketogenic diet to the triple-drug therapy will increase overall survival in patients with pancreatic cancer. This clinical trial began in late 2020 and is anticipated to continue to accrue patients through June 2023.
Patients will be randomly assigned to either receive the triple-drug regimen while on a standard diet, while the other half will receive a ketogenic diet and the triple-drug therapy. The dietary aspects of the study are being carefully monitored.
“Our laboratory experiments show that a ketogenic diet changes pancreatic cancer metabolism and its response to chemotherapy,” said Haiyong Han, Ph.D., a Professor in TGen’s Molecular Medicine Division, and one of the study authors and a designer of the study’s experiments.
Also contributing to this study were: Princeton University, Salk Institute for Biological Studies, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, the Chinese Academy of Sciences, and the Ludwig Institute for Cancer Research.
The preclinical study was funded by: Stand Up to Cancer (SU2C), the National Institutes of Health, Ludwig Cancer Research, the New Jersey Commission on Cancer Research, New Jersey Health Foundation, a Rutgers Busch Biomedical Grant, the Lustgarten Foundation, the Don and Lorraine Freeberg Foundation, and the David C. Copley Foundation.
The clinical trial is being funded by the Purple Pansies and the John E. Sabga Foundation.
Source: Eurekalert
